Famous Patents
Pong, the Atari creation that launched the computer game craze, came with these instructions: "Avoid missing ball for high score."
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| D660418 | Limiter for dispensing device | 05/22/2012 |
| 8168190 | HBV core antigen particles with multiple immunogenic components attached via peptide ligands This invention relates to hepatitis B virus (“HBV”) core antigen particles that are characterized by multiple immunogen specificities. More particularly, the invention relates to HBV core antigen particles comprising immunogens, epitopes, or other related struct... | 05/01/2012 |
| 8163875 | Polymer conjugated glycosylated neublastin The following class of molecule is disclosed: a dimer containing a first neublastin polypeptide and a second neublastin polypeptide, wherein: (a) at least one of the polypeptides is glycosylated; (b) at least one of the polypeptides is conjugated at its N-terminus t... | 04/24/2012 |
| 8153580 | Nogo receptor binding protein The invention provides Sp35 polypeptides and fusion proteins thereof, Sp35 antibodies and antigen-binding fragments thereof and nucleic acids encoding the same. The invention also provides compositions comprising, and methods for making and using, such Sp35 antibodi... | 04/10/2012 |
| 8147829 | Anti-IGR-1R antibodies and uses thereof The invention relates to antibodies which bind to insulin like growth factor receptor-1 (IGF-1R) and uses thereof, in particular in the diagnosis and treatment of cancer. Specific human and murine monoclonal antibodies which inhibit IGF-1R-mediated pro-survival and ... | 04/03/2012 |
| 8142779 | Treatment of follicular lymphomas using inhibitors of the LT pathway Therapeutic uses of inhibitors of the lymphotoxin pathway to treat tumors, specifically to treat follicular lymphomas. ... | 03/27/2012 |
| 8128926 | Sp35 antibodies and uses thereof Endogenous Sp35 is a negative regulator for neuronal survival, axon regeneration, oligodendrocyte differentiation and myelination. Molecules that block endogenous Sp35 function, such anti-Sp35 antibodies can be used as therapeutics for the treatment of neuron and ol... | 03/06/2012 |
| 8124350 | Methods and products for evaluating an immune response to a therapeutic protein The invention relates to methods and products for the identification of a clinically significant immune response in subjects treated with a therapeutic protein. A first aspect of the invention relates to methods and compositions for identifying a clinically signific... | 02/28/2012 |
| 8119114 | Polymer conjugates of mutated neublastin A dimer comprising a mutated neublastin polypeptide coupled to a polymer is disclosed. Such dimers exhibit prolonged bioavailability and, in preferred embodiments, prolonged biological activity relative to wild-type forms of neublastin. ... | 02/21/2012 |
| 8084031 | Method for the treatment of inflammatory disorders A method for the treatment of inflammatory disorders is disclosed, particularly the treatment of arthritis. The method comprises the administration of a function blocking antibody which is capable of binding an epitope of VLA-1. ... | 12/27/2011 |
| 8084028 | Antibodies to VLA-1 Antibodies that specifically bind to VLA-1 integrin and methods of using these antibodies to treat immunological disorders in a subject. Also included are crystal structures of complexes formed by VLA-1 antibodies and their ligands, and VLA-1 antagonists and agonist... | 12/27/2011 |
| 8084026 | Multispecific binding molecules comprising connecting peptides The instant invention describes novel multispecific binding molecules comprising synthetic connecting peptides. The synthetic connecting peptides result in the preferential synthesis of multispecific binding molecules comprising polypeptide chains that are linked vi... | 12/27/2011 |
| 8067375 | Treatment of demyelinating disorders with soluble lymphotoxin-β-receptor Methods of treating a demyelinating disorder using inhibitors of the lymphotoxin pathway. ... | 11/29/2011 |
| 8058406 | Composition comprising antibodies to LINGO or fragments thereof Endogenous LINGO-1 is a negative regulator for neuronal survival, axon regeneration, oligodendrocyte differentiation and myelination. Molecules that block endogenous LINGO-1 function, such anti-LINGO-1 antibodies can be used as therapeutics for the treatment of neur... | 11/15/2011 |
| 8048635 | Measurement of soluble Tweak levels for evaluation of lupus patients Methods of treating patients and evaluating patients for disease stage and/or severity are disclosed. ... | 11/01/2011 |
| 8048422 | Tweak binding antibodies Anti-Tweak antibodies are described. ... | 11/01/2011 |
| 8030456 | Nogo receptor antagonists Disclosed are immunogenic Nogo receptor-1 polypeptides, Nogo receptor-1 antibodies, antigen-binding fragments thereof, soluble Nogo receptors and fusion proteins thereof and nucleic acids encoding the same. Also disclosed are compositions comprising, and methods for... | 10/04/2011 |
| 8026072 | Method of identifying compounds that bind BAFF-R Disclosed are nucleic acids encoding BAFF-R polypeptides, as well as antibodies to BAFF-R polypeptides and pharmaceutical compositions including the same. Methods of treating tumorigenic and autoimmune conditions using the nucleic acids, polypeptides, antibodies and... | 09/27/2011 |
| 8022182 | Truncated BAFF receptors The disclosure provides a non-naturally occurring BAFF-R glycoprotein having a deletion in the extracellular domain which results in an altered O-linked glycosylation pattern. The disclosure also provides methods and pharmaceutical compositions for treating B-cell- ... | 09/20/2011 |
| 8021661 | Cripto binding molecules The invention pertains to humanized forms of an anti-CRIPTO antibody and portions thereof. In one embodiment, the variable regions of these antibodies or polypeptides comprising them (e.g., full-length antibodies or domain deleted antibodies) can be used to treat di... | 09/20/2011 |
| 8017733 | Polyalkylene polymer compounds and uses thereof The invention relates to novel polyalkylene glycol compounds and methods of using them. In particular, compounds comprising a novel polyethylene glycol conjugate are used alone, or in combination with antiviral agents to treat a viral infection, such as chronic hepa... | 09/13/2011 |
| 8003763 | Cripto blocking antibodies and uses thereof The invention provides Cripto blocking antibodies, or biologically functional fragments thereof, and uses thereof. Antibodies which bind Cripto and modulate Cripto signaling are provided. Antibodies which bind Cripto and block the interaction between Cripto and ALK4... | 08/23/2011 |
| 8003504 | Structure and method for fabrication of field effect transistor gates with or without field plates A method for fabrication of a field effect transistor gate, with or without field plates, includes the steps of defining a relatively thin Schottky metal layer by a lithography/metal liftoff or metal deposition/etch process on a semiconductor surface. This is follow... | 08/23/2011 |
| 7968680 | Polynucleotides encoding members of the human B lymphocyte activation antigen B7 family and polypeptides encoded thereby The present invention provides novel isolated BLAA polynucleotides and the membrane-associated or secreted polypeptides encoded by the BLAA polynucleotides. Also provided are the antibodies that immunospecifically bind to a BLAA polypeptide or any derivative, varian... | 06/28/2011 |
| 7960142 | Stabilized polypeptide compositions The invention is based, at least in part, on the development of stabilized binding molecules that consist of or comprise a stabilized scFv and methods for making such stabilized molecules. ... | 06/14/2011 |
| 7951918 | Stabilized polypeptide compositions The invention is based, at least in part, on the development of stabilized binding molecules that consist of or comprise a stabilized scFv and methods for making such stabilized molecules. ... | 05/31/2011 |
| 7951371 | Soluble lymphotoxin-β receptor fusion protein and methods for inhibiting lymphotoxin β-receptor signaling This invention relates to compositions and methods comprising “lymphotoxin-β-receptor blocking agents”, which block lymphotoxin-β receptor signalling. Lymphotoxin-β receptor blocking agents are useful for treating lymphocyte-mediated immunological diseases, a... | 05/31/2011 |
| 7947271 | Methods of decreasing tumor volume and reducing tumor burden using TNF-receptor-coupling agents Receptor coupling agents, including multivalent constructs comprising anti-TNF receptor binding moieties, for treating cancer and inhibiting tumor volume in a subject are disclosed. ... | 05/24/2011 |
| 7943742 | Anti-αβantibodies and uses thereof The present invention is in the fields of cell biology, immunology and oncology. The invention provides humanized antibodies that recognize αvβ6 integrins, which antibodies comprise a variable region of nonhuman origin and at least a portion ... | 05/17/2011 |
| 7927590 | Compositions and methods for inhibiting growth of smad4-deficient cancers The present invention is in the fields of cell biology, immunology and oncology. The invention relates to the discovery that there is a relationship between the expression levels of the tumor suppressor gene smad4 (also known as dpc4) and integrin αvβ | 04/19/2011 |
| 7910099 | Antibodies to VLA-1 Antibodies that specifically bind to VLA-1 integrin and methods of using these antibodies to treat immunological disorders in a subject. Also included are crystal structures of complexes formed by VLA-1 antibodies and their ligands, and VLA-1 antagonists and agonist... | 03/22/2011 |
| 7888479 | Humanized antibodies against monocyte chemotactric proteins The invention provides humanized antibodies that bind to a plurality of b-chemokines, particularly monocyte chemotactic proteins MCP-1, MCP-2 and MCP-3. The invention also provides therapeutic reagents and methods of treating disorders associated with detrimental MC... | 02/15/2011 |
| 7888052 | Cripto blocking antibodies and uses thereof The invention provides Cripto blocking antibodies, or biologically functional fragments thereof, and uses thereof. Antibodies which bind Cripto and modulate Cripto signaling are provided. Antibodies which bind Cripto and block the interaction between Cripto and ALK4... | 02/15/2011 |
| 7846438 | Methods of promoting neurite outgrowth with soluble TAJ polypeptides The invention provides methods of treating diseases, disorders, injuries, or conditions involving modulating neurite outgrowth and/or survival, including CNS disorders, stroke, or spinal injury, by administration of a TAJ antagonist. ... | 12/07/2010 |
| 7863419 | Antibodies having altered effector function and methods for making the same The invention provides a method of producing aglycosylated Fc-containing polypeptides, such as antibodies, having desired effector function. The invention also provides aglycosylated antibodies produced according to the method as well as methods of using such antibo... | 01/04/2011 |
| 7850967 | Method of treating a patient having an autoimmune disorder by administering an antibody that binds human BAFFR Therapeutic regimens for administration of BAFF antagonists for treatment of immunologic and related disorders are described. Regimens involve a short-term BAFF antagonist administration course followed by an extended no-treatment period prior the round of administr... | 12/14/2010 |
| 7838639 | Antibodies to train R: a cysteine-rich member of the TNF-receptor family, and methods of treating tumors expressing said receptor Embodiments of the present invention encompass novel receptors of the TNF family. In particular, embodiments of the invention encompass TNF Receptor in the BRAIN (TRAIN) and isolated antibodies that bind to the same. In some embodiments, isolated antibodies that bin... | 11/23/2010 |
| 7834014 | Aadenosine receptor antagonists The invention is based on the discovery that compounds of formula (I) possess unexpectedly high affinity for the A2a adenosine receptor, and can be useful as antagonists thereof for preventing and/or treating numerous diseases, including Parkinson's disea... | 11/16/2010 |
| 7829092 | Recombinant anti-VLA4 antibody molecules The present invention disclosed recombinant anti-VLA-4 antibody molecules, including humanized recombinant anti-VLA-4 antibody molecules. These antibodies are useful in the treatment of specific and non-specific inflammation, including asthma and inflammatory bowel ... | 11/09/2010 |
| 7799902 | Receptor coupling agents and compositions thereof Receptor coupling agents, including multivalent constructs comprising anti-TNF receptor binding moieties, for treating cancer and inhibiting tumor volume in a subject are disclosed. ... | 09/21/2010 |
